Table 4.
Risk of prostate cancer BCR after prostatectomy associated with GST polymorphisms by race and tumor stage
| Genotype | Total sample | Caucasians | African-Americans | |||
|---|---|---|---|---|---|---|
| Low stage | High stage | Low stage | High stage | Low stage | High stage | |
| GSTM1 |
1.00 (referent) (N = 27)b |
2.48 (1.31–4.69) p = 0.005 (N = 19) |
1.00 (referent) (N = 13) |
2.98 (1.23–7.21) p = 0.02 (N = 14) |
1.00 (referent) (N = 14) |
2.97 (1.16–7.62) p = 0.02 (N = 5) |
| GSTM1 null |
1.38 (0.75–2.53) p = 0.30 (N = 17) |
3.58 (1.82–7.05) p < 0.001 (N = 13) |
1.61 (0.73–3.53) p = 0.24 (N = 9) |
4.89 (2.10–11.43) p < 0.001 (N = 10) |
1.36 (0.48–3.86) p = 0.57 (N = 8) |
2.01 (0.55–7.30) p = 0.29 (N = 3) |
| GSTT1 |
1.00 (referent) (N = 35) |
2.88 (1.68–4.95) p < 0.001 (N = 11) |
1.00 (referent) (N = 23) |
3.46 (1.82–6.58) p < 0.001 (N = 4) |
1.00 (referent) (N = 12) |
2.42 (0.91–6.45) p = 0.08 (N = 7) |
| GSTT1 null |
1.34 (0.68–2.65) p = 0.40 (N = 26) |
2.14 (0.73–6.21) p = 0.16 (N = 4) |
0.82 (0.28–2.40) p = 0.72 (N = 18) |
0.76 (0.10–5.97) p = 0.80 (N = 1) |
2.21 (0.86–5.68) p = 0.10 (N = 8) |
6.20 (1.63–23.58) p = 0.008 (N = 3) |
| GSTP1 Ile/Ile |
1.00 (referent) (N = 18) |
2.39 (1.03–5.54) p = 0.04 (N = 28) |
1.00 (referent) (N = 13) |
3.53 (1.39–8.97) p = 0.008 (N = 14) |
1.00 (referent) (N = 5) |
0.81 (0.09–7.08) p = 0.85 (N = 14) |
| GSTP1 Ile/Val or Val/Val |
0.89 (0.49–1.63) p = 0.70 (N = 8) |
2.42 (1.23–4.76) p = 0.01 (N = 22) |
0.66 (0.30–1.46) p = 0.30 (N = 7) |
2.01 (0.86–4.71) p = 0.11 (N = 12) |
1.24 (0.43–3.56) p = 0.69 (N = 1) |
3.94 (1.25–12.43) p = 0.02 (N = 10) |
| 0–1 High risk GST allelesa |
1.00 (referent) (N = 28) |
2.85 (1.56–5.23) p < 0.001 (N = 18) |
1.00 (referent) (N = 17) |
3.66 (1.72–7.78) p < 0.001 (N = 10) |
1.00 (referent) (N = 11) |
2.69 (0.95–7.65) p = 0.06 (N = 8) |
| 2–3 High risk GST allelesa |
1.29 (0.71–2.35) p = 0.40 (N = 19) |
2.78 (1.35–5.75) p = 0.006 (N = 11) |
1.08 (0.48–2.40) p = 0.85 (N = 12) |
2.47 (0.98–6.24) p = 0.06 (N = 7) |
1.91 (0.75–4.84) p = 0.17 (N = 7) |
3.60 (1.11–11.65) p = 0.03 (N = 4) |
Hazard ratio (HR) and the 95% confidence interval (CI) adjusted for age, race, smoking, tumor grade and PSA at diagnosis
aThe number of high risk alleles refers to the number of GST (GSTM1 null, GSTT1 null and GSTP1 105 Ile/Val or Val/Val) variants carried
bNumber of biochemical failure events (N) in each stratum